リスデキサンフェタミンメシル酸塩
リスデキサンフェタミンメシル酸塩 物理性質
- 闪点 :
- 9℃
- 貯蔵温度 :
- -20°C
- 外見 :
- A neat solid
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
| 絵表示（GHS） |
  
|
| 注意喚起語 |
危険 |
| 危険有害性情報 |
| コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
| H225 |
引火性の高い液体および蒸気 |
引火性液体 |
2 |
危険 |
|
P210,P233, P240, P241, P242, P243,P280, P303+ P361+P353, P370+P378,P403+P235, P501 |
| H370 |
臓器の障害 |
特定標的臓器有害性、単回暴露 |
1 |
危険 |
|
P260, P264, P270, P307+P311, P321,P405, P501 |
|
| 注意書き |
| P210 |
熱/火花/裸火/高温のもののような着火源から遠ざ けること。－禁煙。 |
| P260 |
粉じん/煙/ガス/ミスト/蒸気/スプレーを吸入しないこ と。 |
| P280 |
保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。 |
| P301+P310 |
飲み込んだ場合：直ちに医師に連絡すること。 |
| P311 |
医師に連絡すること。 |
|
リスデキサンフェタミンメシル酸塩 価格
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
リスデキサンフェタミンメシル酸塩 化学特性,用途語,生産方法
効能
中枢神経刺激薬
商品名
ビバンセ (塩野義製薬)
説明
ADHD is a neurobehavioral disorder characterized by varying degrees of
inattention, hyperactivity, and impulsivity. ADHD is typically diagnosed in
childhood and affects 7–12% of the pediatric population in the United States with
the condition often enduring into adulthood.
While the precise mechanism of action of lisdexamfetamine
in treating ADHD is not known, amphetamines are believed to inhibit the
reuptake of the neurotransmitters dopamine and noradrenaline (norepinephrine),
thereby increasing their presynaptic availability and release into extraneuronal space. The prodrug is constructed by the condensation of D-amphetamine with the activated ester (N-hydroxysuccinimide) of bis-tert-butoxycarbonylprotected L-lysine. Lisdexamfetamine is ultimately generated by treatment with hydrochloric acid in dioxane.
The most common adverse events, comparable to other amphetamine formulations, were decreased appetite, insomnia, upper abdominal pain, and irritability. Lisdexamfetamine is contraindicated in patients with advanced arteriosclerosis, symptomatic cardiovascular disease, moderate-to-severe hypertension, hyperthyroidism, known hypersensitivity to the sympathomimetic amines, glaucoma, a predisposition to agitated states, and a history of drug abuse. In addition, the drug should not be administered during or within 14 days of treatment with monoamine oxidase inhibitors. It has also been noted that psychostimulants may exacerbate symptoms of pre-existing psychotic disorders, so caution and close observation are recommended in this patient population.
使用
Treatment of atten tion deficit hyperactivity disorder (ADHD).
リスデキサンフェタミンメシル酸塩 上流と下流の製品情報
原材料
準備製品
リスデキサンフェタミンメシル酸塩 生産企業
Global( 48)Suppliers
608137-33-3(リスデキサンフェタミンメシル酸塩)キーワード:
- 608137-33-3
- Nrp 104
- Nrp-104
- Spd 489
- Spd489
- Lisdexamfetamine dimesylate solution
- Lisdexamfetamine (mesylate) (exempt preparation)
- (2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide,methanesulfonic acid
- (2S)-2,6-DIAMINO-N-[(1S)-1-METHYL-2-PHENYLETHYL]HEXANAMIDE DIMETHANESULFONATE USP/EP/BP
- Lisdexamphetamine 13CD3 Dimesylate
- Lisdexamfetamine mesilate
- Lisdexamfetamine (mesylate) (CRM)
- Lisdexamphetamine Dimesylate (1mg/ml in Methanol)
- Lisdexamphetamine-Dimesylate
- Lisdexamfetamine mesylate
- Ldx
- Lisdexamfetamine dimesylate
- (2S)-2,6-Diamino-N-[(1S)-1-methyl-2-phenylethyl]hexanamide dimethanesulfonate
- リスデキサンフェタミンメシル酸塩
- リスデキサンフェタミンメシル酸塩 (JAN)